Chugai Pharmabody

Global Chugai News Release

Friday, 21 February 2020 7:00 AM

Chugai Obtains Approval for Additional Indication of Alecensa for Recurrent or Refractory ALK Fusion Gene-Positive Anaplastic Large Cell Lymphoma

Friday, 21 February 2020 7:00 AM

Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Friday, 21 February 2020 7:00 AM

Anti-CD20 Monoclonal Antibody “Rituxan®,” Approved for Additional Indication of Acquired Thrombotic Thrombocytopenic Purpura